These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 17646232)
21. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Creaney J; Dick IM; Segal A; Musk AW; Robinson BW Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718 [TBL] [Abstract][Full Text] [Related]
22. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566 [TBL] [Abstract][Full Text] [Related]
23. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic. Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044 [TBL] [Abstract][Full Text] [Related]
24. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of serum mesothelin in malignant and benign ovarian masses. Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964 [TBL] [Abstract][Full Text] [Related]
26. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. Creaney J; Segal A; Olsen N; Dick IM; Musk AW; Skates SJ; Robinson BW Dis Markers; 2014; 2014():413946. PubMed ID: 25505814 [TBL] [Abstract][Full Text] [Related]
27. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Grigoriu B; Chahine B; Zerimech F; Grégoire M; Balduyck M; Copin MC; Devos P; Lassalle P; Scherpereel A Clin Biochem; 2009 Jul; 42(10-11):1046-50. PubMed ID: 19302997 [TBL] [Abstract][Full Text] [Related]
28. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138 [TBL] [Abstract][Full Text] [Related]
29. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568 [TBL] [Abstract][Full Text] [Related]
30. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616 [TBL] [Abstract][Full Text] [Related]
31. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982 [TBL] [Abstract][Full Text] [Related]
32. Soluble mesothelin-related protein--a blood test for mesothelioma. Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789 [TBL] [Abstract][Full Text] [Related]
33. Mesothelin-family proteins and diagnosis of mesothelioma. Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I Lancet; 2003 Nov; 362(9396):1612-6. PubMed ID: 14630441 [TBL] [Abstract][Full Text] [Related]
34. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure. Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653 [TBL] [Abstract][Full Text] [Related]
36. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Di Serio F; Fontana A; Loizzi M; Capotorto G; Maggiolini P; Mera E; Bisceglia L; Molinini R Clin Chem Lab Med; 2007; 45(5):634-8. PubMed ID: 17484626 [TBL] [Abstract][Full Text] [Related]
37. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. Hollevoet K; Reitsma JB; Creaney J; Grigoriu BD; Robinson BW; Scherpereel A; Cristaudo A; Pass HI; Nackaerts K; Rodríguez Portal JA; Schneider J; Muley T; Di Serio F; Baas P; Tomasetti M; Rai AJ; van Meerbeeck JP J Clin Oncol; 2012 May; 30(13):1541-9. PubMed ID: 22412141 [TBL] [Abstract][Full Text] [Related]
38. Correlation of serum-soluble mesothelin-related protein, HMGB1 and CA125 in diffuse malignant peritoneal mesothelioma and their combined measurement for prognosis. Wang L; Wang X; Sun N; Chen B Scand J Clin Lab Invest; 2023 Apr; 83(2):74-78. PubMed ID: 36705231 [TBL] [Abstract][Full Text] [Related]
39. Validity of mesothelin in occupational medicine practice. Smolková P; Nakládalová M; Zapletalová J; Jakubec P; Vildová H; Kolek V; Petřek M; Nakládal Z Int J Occup Med Environ Health; 2016; 29(3):395-404. PubMed ID: 26988879 [TBL] [Abstract][Full Text] [Related]
40. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]